KR20090086627A - 프로드러그 및 그것의 제조 및 사용 방법 - Google Patents

프로드러그 및 그것의 제조 및 사용 방법 Download PDF

Info

Publication number
KR20090086627A
KR20090086627A KR1020097013918A KR20097013918A KR20090086627A KR 20090086627 A KR20090086627 A KR 20090086627A KR 1020097013918 A KR1020097013918 A KR 1020097013918A KR 20097013918 A KR20097013918 A KR 20097013918A KR 20090086627 A KR20090086627 A KR 20090086627A
Authority
KR
South Korea
Prior art keywords
hydrogen
compound
prodrug
prodrug moiety
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097013918A
Other languages
English (en)
Korean (ko)
Inventor
나위드 무함마드
키이스 알. 블레이
Original Assignee
노이로제스엑스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노이로제스엑스, 인코포레이티드 filed Critical 노이로제스엑스, 인코포레이티드
Publication of KR20090086627A publication Critical patent/KR20090086627A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020097013918A 2006-12-05 2007-12-05 프로드러그 및 그것의 제조 및 사용 방법 Withdrawn KR20090086627A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87351906P 2006-12-05 2006-12-05
US60/873,519 2006-12-05

Publications (1)

Publication Number Publication Date
KR20090086627A true KR20090086627A (ko) 2009-08-13

Family

ID=39361296

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097013918A Withdrawn KR20090086627A (ko) 2006-12-05 2007-12-05 프로드러그 및 그것의 제조 및 사용 방법

Country Status (12)

Country Link
US (1) US20080318905A1 (enExample)
EP (1) EP2121029A2 (enExample)
JP (1) JP2010511717A (enExample)
KR (1) KR20090086627A (enExample)
CN (1) CN101678120A (enExample)
AU (1) AU2007328007A1 (enExample)
BR (1) BRPI0719937A2 (enExample)
CA (1) CA2671737A1 (enExample)
MX (1) MX2009006007A (enExample)
NO (1) NO20092527L (enExample)
RU (1) RU2009125597A (enExample)
WO (1) WO2008070149A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
JP5221514B2 (ja) * 2007-03-06 2013-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定性が改善されたクロロメチルフォスフェイト誘導体を含む組成物及びその製造方法
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
BRPI0912326A2 (pt) 2008-05-20 2015-10-06 Neurogesx Inc análogos de acetaminofeno hidrossolúveis
EP2285419A4 (en) 2008-05-20 2012-05-02 Neurogesx Inc LUBRICANT MUTUAL PARACETAMOL PRODRUGS
CA2724881C (en) 2008-05-20 2016-09-27 Neurogesx, Inc. Carbonate prodrugs and methods of using the same
MX2011001053A (es) 2008-07-28 2011-04-21 Pfizer Compuestos de fenantrenona, composiciones y metodos.
US20100076198A1 (en) * 2008-09-19 2010-03-25 Mallinckrodt Inc. Crystalline forms of Fentanyl Alkaloid
HUE033442T2 (en) 2009-06-25 2017-11-28 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
EP2445343B1 (en) 2009-06-25 2021-08-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
JP5848761B2 (ja) 2010-06-24 2016-01-27 アルカーメス ファーマ アイルランド リミテッド Ｎｈ酸性化合物のプロドラッグ：エステル、カルボネート、カルバメートおよびホスホネートの誘導体
EP3156056B1 (en) 2011-03-18 2023-12-06 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
PH12014500049A1 (en) * 2011-07-28 2016-07-29 Kempharm Inc Methylphenidate-prodrugs, processes of making and using the same
CA2849731C (en) 2011-09-22 2020-01-14 Acorda Therapeutics, Inc. Acetaminophen conjugates, compositions and methods of use thereof
JP5952912B2 (ja) 2011-12-15 2016-07-13 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
AU2013235526B2 (en) 2012-03-19 2017-11-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
ES2792149T3 (es) 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
EP2986295A4 (en) 2013-04-17 2016-11-09 Biopharma Works PROCESS FOR PAIN TREATMENT
EP2986294A4 (en) 2013-04-17 2016-11-16 Biopharma Works PROCESS FOR PAIN TREATMENT
ES2718211T3 (es) 2013-05-24 2019-06-28 Rhodes Tech Compuestos cetales opioides y usos de los mismos
US9969746B2 (en) 2013-12-05 2018-05-15 The University Of Bath Opioid compounds and their uses
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
ES2922976T3 (es) * 2015-05-13 2022-09-22 4P Pharma Apomorfina para el tratamiento de la hiperactividad inducida por metilfenidato
US20170273974A1 (en) * 2016-03-24 2017-09-28 Medrx Co., Ltd Patch preparations with misuse prevention features
EP3703694A4 (en) * 2017-11-03 2021-08-18 Nirsum Laboratories, Inc. MEDICINES ANTAGONISTS OF OPIOID RECEPTORS
AU2019224127B2 (en) 2018-02-23 2021-12-09 Rhodes Technologies Novel opioid compounds and uses thereof
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
WO2020012248A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Novel naphthylenyl compounds for long-acting injectable compositions and related methods
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
EP3863629A4 (en) * 2018-10-13 2022-06-22 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of cgrp antagonists
WO2020094634A1 (en) 2018-11-05 2020-05-14 Alkermes Pharma Ireland Limited Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods
KR20220005554A (ko) * 2019-05-07 2022-01-13 브리스톨-마이어스 스큅 컴퍼니 전구약물 화합물
FI130262B (en) * 2019-08-30 2023-05-17 Medicortex Finland Oy Formulations and compositions for use in the prevention or treatment of brain injury and neurodegenerative diseases
CN114761082A (zh) * 2019-09-30 2022-07-15 日本化学药品株式会社 氮杂环庚烷衍生物
CN114380859B (zh) * 2020-10-22 2024-11-01 威智医药股份有限公司 磷酸二苄酯及焦磷酸四苄酯的制备方法
CN117805249A (zh) * 2022-09-23 2024-04-02 合肥瀚微生物科技有限公司 一种抑郁症诊断的生物标记物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
AU773642C (en) * 1997-12-22 2006-04-06 Mundipharma Pty Limited Opioid agonist/antagonist combinations
DE69822514T2 (de) * 1997-12-31 2005-03-24 The University Of Kansas, Lawrence Wasserlösliche pro-pharmaka von arzneistoffen, die ein tertiäres amin enthalten, und verfahren zu ihrer herstellung
US6703398B2 (en) * 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
EP1603597B1 (en) * 2003-03-13 2010-01-06 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
HUE037643T2 (hu) * 2004-06-12 2018-09-28 Collegium Pharmaceutical Inc Visszaélésre nem alkalmas gyógyszerkészítmények

Also Published As

Publication number Publication date
AU2007328007A1 (en) 2008-06-12
WO2008070149A3 (en) 2009-12-10
WO2008070149A2 (en) 2008-06-12
US20080318905A1 (en) 2008-12-25
MX2009006007A (es) 2009-07-17
BRPI0719937A2 (pt) 2014-03-11
RU2009125597A (ru) 2011-01-20
JP2010511717A (ja) 2010-04-15
CN101678120A (zh) 2010-03-24
EP2121029A2 (en) 2009-11-25
CA2671737A1 (en) 2008-06-12
NO20092527L (no) 2009-09-04

Similar Documents

Publication Publication Date Title
KR20090086627A (ko) 프로드러그 및 그것의 제조 및 사용 방법
KR101698028B1 (ko) 수용성 아세트아미노펜 유사체
EP2448407B1 (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
ES2750825T3 (es) Compuestos de morfinano deuterados
US8461171B2 (en) Hybrid opioid compounds and compositions
KR101589846B1 (ko) 히드로모르폰의 벤조산, 벤조산 유도체 및 헤테로아릴 카르복실산 컨쥬게이트, 전구약물, 이의 제조 방법 및 용도
US9586954B2 (en) N-substituted noribogaine prodrugs
CN110090308B (zh) 制备偶联物的方法
AU2021215274B2 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
KR101430626B1 (ko) 부프레노르핀 유도체 및 이들의 용도
US20120149900A1 (en) Fluorine containing compounds and methods of use thereof
JP5657394B2 (ja) 疼痛の治療又は予防方法
JP2008526846A (ja) 鎮痛性結合体
JP2008512462A (ja) ナルメフェン及びそれの類似体を使用する疾患の処置
EP3406614B1 (en) Opioid receptor antagonist conjugate and use thereof
US8133881B2 (en) Carbohydrate conjugates to prevent abuse of controlled substances
TWI837128B (zh) 萘普生(ｎａｐｒｏｘｅｎ)及普加巴林(ｐｒｅｇａｂａｌｉｎ)之1-(醯氧基)-烷基胺甲酸酯之藥物結合物的結晶型
CN108210933A (zh) 一种地佐辛与聚乙二醇的结合物
HK1142543A (en) Prodrugs and methods of making and using the same
RU2799809C2 (ru) Кристаллические формы 1-(ацилокси)-алкилкарбаматных конъюгатов лекарственных средств напроксена и прегабалина
CA3149152A1 (en) Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates
EP1882692A1 (en) Dimethano-[1,3]dioxocino[6,5-D]pyrimidine-spiro derivatives of tetrodotoxin, process for their synthesis and uses thereof in the treatment of pain
HK1263115A1 (en) Opioid receptor antagonist conjugate and use thereof
AU2403799A (en) Therapeutic compounds
WO2003011828A2 (en) 3-pyridylether rerivatives and their use as analgesics

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090703

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid